Stockreport

Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

PLUS THERAPEUTICS, Inc.  (PSTV) 
PDF Began enrollment of the 5th of an anticipated 7 planned dosing cohorts for the ReSPECT-LM Phase 1 dose escalation trial with rhenium (186Re) obisbemeda for leptomeningea [Read more]